title: Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization.
abstract: We examined serum levels of the angiogenic factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF), in normal donors for allogeneic peripheral blood stem cell (PBSC) transplantation. Granulocyte colony-stimulating factor (G-CSF) (filgrastim 400 microg/m2/d) was administered to 23 donors for 5 d and aphereses were performed on days 4 and 5. Although bFGF remained at similar levels after G-CSF treatment, serum VEGF and HGF levels increased 1.5-fold (n = 13; P = 0.02) and 6.8-fold (n = 23; P < 0.0001) respectively. The serum HGF level before G-CSF administration on day 1 correlated inversely with mobilized CD34+ cell numbers. Time course kinetics of HGF showed that on the day after G-CSF administration (day 2), serum HGF levels increased to 3678 pg/ml. For auto PBSC mobilization with chemotherapy and G-CSF 200 microg/m2/d (n = 8), we observed similar HGF elevation, which appeared to be dose-dependent on the G-CSF administered.
authors.affiliation: Department of Medicine, University of Okayama, 2-5-1 Shikatacho, Okayama 700-8558, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Fujii
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ishimaru
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Kozuka
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakase
authors.forename: Itaru
authors.initials: I
authors.lastname: Kataoka
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tabayashi
authors.forename: Katsuji
authors.initials: K
authors.lastname: Shinagawa
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006402:Hematologic Diseases / Q000097:blood / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D016179:Granulocyte Colony-Stimulating Factor; D017228:Hepatocyte Growth Factor; D000069585:Filgrastim